Gene Therapy: Expectations and Results

Abstract

Industry has invested heavily in gene therapy since the first clinical trial in 1989. Ethical debates, regulations and public expectations have had a major impact on its commercial development.

Keywords: gene therapy; biotechnology industry; public perception; clinical development; ethics

References

Cavazzana‐Calvo M, Hacein‐Bey S, de Saint Basile G, et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)‐X1 disease. Science 288 (April 28): 669–672.

Journal of Gene Medicine (2002) Gene Therapy Clinical Trials. http://www.wiley.co.uk/wileychi/genmed/clinical/

Martin P (1998) From eugenics to therapeutics: the impact of opposition on the development of gene therapy in the USA. In: Wheale P, von Schomberg R and Glasner P (eds.) The Social Management of Genetic Engineering. Aldershot, UK: Ashgate Publishing.

Martin PA (1999) Genes as drugs: the social shaping of gene therapy and the reconstruction of genetic disease. Sociology of Health and Illness 21(5): 517–538.

Martin PA (2001) Great expectations: the construction of markets, products and user needs during the early development of gene therapy in the USA. In: Coombs R, Green K, Walsh V and Richards A (eds.) Technology and the Market: Demand, Users and Innovation. Cheltenham, UK: Edwards Elgar.

Martin P and Thomas S (1996) The Development of Gene Therapy in Europe and the United States: A Comparative Analysis, STEEP Special Report no. 5. Brighton, UK: Science Policy Research Unit, University of Sussex.

Martin PA, Crowther S, Corneliussen F, Jaeckel G and Reiss T (2000) Gene Therapy in Europe: Exploitation and Commercial Development, Final Project Report. Brighton, UK: Science Policy Research Unit, University of Sussex.

Nelson D and Weiss R (2000) Gene researchers admit mistakes, deny liability. Washington Post February 15: A03.

Tatum EL (1966) Molecular biology, nucleic acids and the future of medicine. Perspectives in Biology and Medicine Autumn: 19–32.

Further Reading

Lyon J and Gorner P (1996) Altered Fates: Gene Therapy and the Retooling of Human Life. New York, NY: WW Norton.

McCormick F (2001) Cancer gene therapy: fringe or cutting edge? Nature Reviews Cancer 1(2): 130–141.

Scollay R (2001) Gene therapy: a brief overview of the past, present, and future. Annals of the New York Academy of Sciences 953: 26–30. [Also see series of other articles in the same volume.]

Web Links

Journal of Gene Medicine. Provides profiles of leading gene therapy firms. http://www.wiley.co.uk/wileychi/genmed/companies/

Human Genome Project Information. Introduction to Gene Therapy http://www.ornl.gov/hgmis/medicine/genetherapy.html

National Reference Center for Bioethics Literature Scope Note 24: Outline of the history of the main ethical debates. http://www.georgetown.edu/research/nrcbl/scopenotes/sn24.html

Office of Biotechnology Activities. Recombinant DNA and Gene Transfer. Information on regulations and current developments. http://www4.od.nih.gov/oba/Rdna.htm

National Heart, Lung and Blood Institute. Programs of Excellence in Gene Therapy. Links to leading research centres. http://med.cornell.edu/pegt/

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Martin, Paul A(Sep 2006) Gene Therapy: Expectations and Results. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0005653]